Any feedback?
Literature summary for 3.4.21.5 extracted from
- A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience (2008), J. Thromb. Thrombolysis, 28, 117-123.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | comparison of thrombin inhibitors lepirudin and argatroban for treatment of heparin-induced thrombocytopenia. Adult subjects with a positive anti-heparin platelet factor 4 antibody test and more than 50% decrease in platelet count during the first 30 days of admission over a period of 2 years were included in the study. Subjects treated with a thrombin inhibitor are more likely to experience platelet count recovery, with 87.5% for the lepirudin group and 82.4% for the argatroban group, compared to those who do not receive antithrombin therapy. The thrombosis rate for subjects who do not receive antithrombin therapy after the diagnosis of heparin-induced thrombocytopenia is 26.8%, compared to 8.3% for the lepirudin group and 5.9% for the argatroban group | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| argatroban | - |
Homo sapiens |  |
| lepirudin | - |
Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
patients with heparin-induced thrombocytopenia | - |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
